In particular, studies of prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are being conducted [14], including the use of lutetium-177 [177Lu]-PSMA-617 in men with metastatic prostate cancer [15,16]. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.